Here's a look at new botulinum toxin treatments on the horizon.
Ustekinumab has a higher drug survival rate than adalimumab, etanercept and infliximab, confirms a study of plaque psoriasis patients published in the Journal of Cutaneous Medicine and Surgery.
In inflammatory arthritis, the molecular and genetic makeup of synovial tissues appears to hold clues that one day may guide clinical decision-making. Re: EULAR report.
This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.
A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.
Despite the popularity of fractional ablative resurfacing, full-field erbium resurfacing still has an important role in skin rejuvenation.
Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.
The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD.
Publishing new research findings has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this table on page 98 of Dermatology Times June issue, we feature insights from three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from this year's Winter Clinical Dermatology Conference.
Brodalumab most cost-effective with high efficacy for plaque psoriasis, but IL-17 inhibitors as a whole outperform other biologics, study shows.